Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30625865 | 1.00 | LMNA (0.46) | LMNACYP3A4PKMNPSR1ALDH1A1 | |
| SCHEMBL8117428 | 0.75 | LMNA (0.35) | LMNACYP3A4PKMNPSR1ALDH1A1 | |
| SCHEMBL10733995 | 0.75 | LMNA (0.41) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL5961698 | 0.74 | LMNA (0.51) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL8948774 | 0.74 | CYP3A4 (0.35) | CYP3A4ALDH1A1 | |
| SCHEMBL7935652 | 0.73 | LMNA (0.58) | LMNAALDH1A1KDM4EMAPTPOLB | |
| SCHEMBL435089 | 0.72 | LMNA (0.49) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL8948551 | 0.72 | HPGD (0.44) | LMNACYP3A4ALDH1A1KDM4EMAPT | |
| SCHEMBL321702 | 0.71 | LMNA (0.49) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL10737745 | 0.70 | PKM (0.50) | LMNAPKMNPSR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NodThera Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-111356680-B | Selective inhibitors of NLRP3 inflammasome | 诺瑟拉有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-3571187-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH INC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220306649-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20210395268-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3331864-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| CN-111356680-A | Selective inhibitors of NLRP3inflammasome | 诺瑟拉有限公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-3661921-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | Nodthera Limited (GB) | 2020-06-10 | — | — | EP | disclosed |
| US-20190337965-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2019-11-07 | — | — | US | disclosed |
| WO-2019025467-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019025467-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2019-02-07 | — | — | WO | disclosed |
| WO-2018136890-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | JECURE THERAPEUTICS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | LMNA 4393/4885CYP3A4 3025/4885PKM 1176/4885 |
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NLRP3, NOD1, NLRP1 | LMNA 1234/4885CYP3A4 2832/4885PKM 3705/4885 |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | LMNA 1234/4885CYP3A4 2832/4885PKM 3705/4885 |
| US-20190337965-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | LMNA 4355/4885CYP3A4 3414/4885PKM 4022/4885 |
| US-20210395268-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | LMNA 4355/4885CYP3A4 3414/4885PKM 4022/4885 |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | LMNA 4355/4885CYP3A4 3414/4885PKM 4022/4885 |
| US-20220306649-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | LMNA 4355/4885CYP3A4 3414/4885PKM 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.